Humanigen Inc (fka HGENQ)

[cowtown jay]

I suspect that we may be looking at using a vaccine to develop a post-exposure prophylaxis, somewhat as Evusheld is using a vaccine with their pre-exposure prophylaxis. I am not, and have not meant, to suggest that Evusheld be used with lenz.

"Pre-exposure prophylaxis with Evusheld is not a substitute for vaccination in individuals for
whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who
may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination. In individuals who have received a COVID-19 vaccine, Evusheld should be administered at
least two weeks after vaccination."

bottom pg 1

https://www.fda.gov/media/154703/download


So there is likely data available in regards to using a vaccine along with a mAb.

And speaking of test data, since NIAID excluded patients on room air and/or in ordinal scale 4 from their ACTIV-5 patient population, I wonder if Johns Hopkins can compile, or is compiling, another case cohort study of their patients at that disease progression level from their IND treatments. We can include that data, along with the ACTIV-5 data for NIAID's ordinal scale 5 trial patients, when we re-submit our EUA application.

I don't think that it will take years to compile this data. I don't think the country/world could wait that long.